Navigation Links
Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments
Date:8/3/2009

atory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for weight management. Arena has a broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, which includes compounds being evaluated independently and with partners, including Merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about future activities, results and announcements relating to lorcaserin, including the BLOSSOM results, the submission of a lorcaserin NDA, the content of such NDA, and the submission of the BLOOM-DM results as a supplement to the NDA; the development, advancement, therapeutic indication, tolerability, safety, selectivity and efficacy of lorcaserin; the protocol, design, scope, enrollment and other aspects of the lorcaserin trials; the potential of lorcaserin in managing weight, improving health and generating commercial and other interest; Arena's financial position and its impact on Arena's abilities; the approval of lorcaserin for marketing; partnering discussions; financial guidance; the decline of Arena's research and development expenses; cost savings from Arena's reduction in force and other cost-containment efforts; dosing in lorcaserin clinical trials expected to be included in the planned NDA submission; Arena's agreements with Azimuth and Deerfield and rights and future activities thereunder; and Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Arena Pharmaceuticals Announces Public Offering of Common Stock
3. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
4. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
7. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
9. Field Poll: California Nurses Association Most Favorably Viewed Group in Healthcare Arena
10. Childrens Miracle Network and Arena Football League Partner for First Nationwide Celebration Event
11. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Kathleen Doheny HealthDay Reporter ... urine test can routinely spot human papillomavirus (HPV), which is ... found. "Our study shows that testing urine for HPV ... the cervix for HPV," said lead researcher Dr. Neha Pathak. ... fellow at Queen Mary University of London, England. The ...
(Date:9/16/2014)... 2014 These new programs allow those who ... receive up to $10,000 in a 0% interest free, 2nd ... other state and federal programs, are listed on their private ... until you sell or move out of the property. The ... loan. There are no monthly payments paid by the Borrower. ...
(Date:9/16/2014)... A new study found that fractional flow ... true coronary bifurcation lesions yields similar outcomes to ... trial is the first study to compare FFR-guided ... today at the 26th annual Transcatheter Cardiovascular Therapeutics ... Foundation (CRF), TCT is the world,s premier educational ...
(Date:9/16/2014)... Washington, DC (PRWEB) September 16, 2014 ... could potentially yield hundreds of billions of dollars in ... 2007 report by the Commonwealth Fund. To help spur ... is seeking up to 10 collaborative groups from across ... 1.0 ( http://bit.ly/1wo4gsa ) - a handbook designed ...
(Date:9/16/2014)... Angeles, CA (PRWEB) September 16, 2014 ... League of United Latin American Citizens (LULAC) will host ... LULAC’s Feria de Salud will feature free health screenings ... Other free testing includes glucose and cholesterol levels as ... will be available for children under 6 years old ...
Breaking Medicine News(10 mins):Health News:Urine Test for HPV Works Well, Analysis Finds 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 3Health News:Results of DKCRUSH-VI trial reported at TCT 2014 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 3Health News:LULAC Hosts Second Annual Latinos Living Healthy Feria de Salud in Los Angeles 2
... ... is giving away 10,000 free business card pens. , ... (PRWEB) December 2, 2009 -- National Pen ( www.pens.com ), a ... pens. , , , , ,“We have a new way to promote business that no ...
... ... direct microwave signal transmissions away from users will be available in early 2010 from ... ... signal transmissions away from users will be available in early 2010 from Aerius International ...
... ... and walkers from Las Vegas and around the country will cross the ... by Zappos.com, raising over $3.2 million for the Crohn,s & Colitis Foundation ... charity of the race, the funds will go toward research, education, and ...
... 2 The American Health Information Management Association,s Board ... be the next chief executive of the 55,000-member health ... information experience includes academia, systems management, strategic expertise, governance ... scheduled to take office January 13, 2010. , "Dr. ...
... , , WASHINGTON, Dec. ... 2 in their campaign against the U.S. House bill,s pro-life ... CEO Charmaine Yoest released this statement in response to the ... "By confusing abortion with health care, the feminist groups and ...
... Washington Post Highlights Dangers , WASHINGTON, ... way, many medical treatments and preventative measures we take for granted may ... to bear on the debate over healthcare reform has been widely reported. ... likely impact if that pressure to influence healthcare policy is not curtailed. ...
Cached Medicine News:Health News:National Pen Giving Away 10,000 Business Card Pens 2Health News:New AERIUS Cell Phones Direct Microwave Signals Away from Users 2Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 2Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 3Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 4Health News:Dr. Alan F. Dowling Named AHIMA's Next Chief Executive Officer 2Health News:Everybody's Healthcare Is Threatened by Catholic Bishops' Interference 2
(Date:9/16/2014)... , Sept. 16, 2014 Astellas announced ... of Business Communications & Advocacy, Urology in the ... Communications & Advocacy Margaret Long. In this role, Noland ... urology to patient and advocacy organizations, as well ... key strategic initiatives. Noland,s appointment is the latest ...
(Date:9/16/2014)... YORK , Sept. 16, 2014 This report ... by the following Product Segments: Devices, and Medication. The report ... , Japan , Europe ... America , and Rest of World. Annual estimates and ... a seven-year historic analysis is provided for these markets. Market ...
(Date:9/16/2014)... Wash. , Sept. 16, 2014 /PRNewswire/ ... a late stage development company engaged primarily ... medical isotopes for diagnostic and therapeutic applications, ... for technology related to its brachytherapy products.  ... arise from its license from Battelle, under ...
Breaking Medicine Technology:Christy Noland to Lead Urology Advocacy and Communications for Astellas 2Global Foot Care Products Industry 2Global Foot Care Products Industry 3Global Foot Care Products Industry 4Global Foot Care Products Industry 5Global Foot Care Products Industry 6Global Foot Care Products Industry 7Global Foot Care Products Industry 8Global Foot Care Products Industry 9Global Foot Care Products Industry 10Global Foot Care Products Industry 11Global Foot Care Products Industry 12Global Foot Care Products Industry 13Global Foot Care Products Industry 14Global Foot Care Products Industry 15Global Foot Care Products Industry 16Global Foot Care Products Industry 17Global Foot Care Products Industry 18Global Foot Care Products Industry 19Global Foot Care Products Industry 20Global Foot Care Products Industry 21Global Foot Care Products Industry 22Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4
... loss of Arf gene in presence of BCR-ABL ... of the bone,marrow, helping cells develop immunity to ... 29 Results of a study,by investigators at ... why the drug imatinib (Gleevec(TM)), which has revolutionized,the ...
... from Roche-, MONTVALE, N.J., Aug. 29 ... the dosing of the,first subject in the single ... program of R4996/MEM 63908, a partial agonist of ... could be beneficial in,the treatment of Alzheimer,s disease ...
Cached Medicine Technology:St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia 2Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908 2Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: